loader2
Login Open ICICI 3-in-1 Account
  • Text Size
  • Text to Speech
  • Color Contrast
  • Pause Animations
IPOLogoImag

MOLBIO DIAGNOSTICS IPO

CLOSED

IPO Details

ICICI Direct Research Rating : SUBSCRIBE
10th Aug 2026
12th Aug 2026
18
₹ 13,824
₹ 768-807
₹ 940 Crore

Issue timeline

  • 10-12 Aug 2026
  • 13-Aug-2026
  • 14-Aug-2026
  • 14-Aug-2026
  • 17-Aug-2026

Subscription Status

Shareholder -
Qualified Institutional Buyers -
Non-Institutional Investor -
Retail Individual Investor -
Employee -
Total -

About Company

Molbio Diagnostics was incorporated on October 20, 2000. The company develops innovative point-of-care diagnostics through its patented ‘Truenat’ PCR platform, enabling rapid testing for 30 diseases across 100 countries. It also offers radiology, digital pathology, and breast health solutions while building a pipeline of new products
-
Name Designation
Sriram Natarajan Executive Director & Chief Executive Officer
Chandrasekhar Bhaskaran Nair Executive Director & Chief Technology Officer
Sangeetha Sriram Executive Director & Director Operations
Arun Kumar Jha Independent Director
Balram Bhargava Independent Director
Nupur Garg Independent Director

Objectives

Funding capital expenditure towards the setting up of infrastructure for the research and development facility, Centre of Excellence and connected office space
Funding capital expenditure towards the purchase of certain plant, machinery and other equipment for the Goa & Visakhapatnam Units
General corporate purposes

Strengths & Risks

Strengths (3)

The company has strong in-house R&D through its subsidiary Bigtec, with a proven record of developing innovative POC diagnostic platforms. Its 13+ years of research led to ICMR-certified solutions, including one of the earliest POC PCR platforms for influenza and swine flu diagnosis

Risks (3)

The company’s sales cycle is complex and variable, involving multiple stakeholders such as clinicians, pathologists, and laboratories. Dependence on clinician prescriptions, government orders, and lengthy approval processes often leads to delays and fluctuations in demand, making accurate sales forecasting challenging

Financials

Frequently Asked Questions

What is the issue type for Molbio Diagnostics Ltd.?

This IPO consists of an offer for sale of up to Rs 739.7 crore, of 9,166,000 shares. It also consists of a fresh issue of Rs 200.0 crore.

The promoters of the company are Sriram Natarajan, Chandrasekhar Bhaskaran Nair, Sangeetha Sriram, Shiva Sriram, Sowmya Sriram and Exxora Trading LLP.

The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.

The price band of the IPO is Rs 768.0 - 807.0.

The IPO application opens on Aug 10, 2026 and closes on Aug 12, 2026.

View More

*The financials mentioned above are sourced from DRHP/ RHP documents.